GSK plc (LON:GSK)
1,894.00
-20.00 (-1.04%)
Oct 23, 2026, 4:56 PM BST
GSK plc Employees
GSK plc had 66,841 employees as of December 31, 2025. The number of employees decreased by 1,788 or 2.61% compared to the previous year. That makes GSK plc the 525th largest employer in the world and 22nd in the United Kingdom.
Employees
66,841
Change (1Y)
-1,788
Growth (1Y)
-2.61%
Revenue / Employee
496.75K GBP
Profits / Employee
72.13K GBP
Market Cap
75.89B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 66,841 | -1,788 | -2.61% |
| Dec 31, 2024 | 68,629 | -1,583 | -2.25% |
| Dec 31, 2023 | 70,212 | 812 | 1.17% |
| Dec 31, 2022 | 69,400 | -20,696 | -22.97% |
| Dec 31, 2021 | 90,096 | -3,970 | -4.22% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| AstraZeneca | 96,100 |
| Haleon | 24,535 |
| Spire Healthcare Group | 17,800 |
| Smith & Nephew | 17,000 |
| Convatec Group | 10,000 |
| Hikma Pharmaceuticals | 9,500 |
| CVS Group | 9,000 |
| Genus | 2,921 |
GSK plc News
- 3 days ago - Ionis Pharmaceuticals Announces FDA Approval of HIBSAGO, Eligible for 10-12% Royalties - Nasdaq
- 3 days ago - GSK’s ViiV announce real-world evidence from OPERA cohort using Cabenuva - TheFly
- 3 days ago - Ionis Pharmaceuticals partner GSK announces FDA approval of Hibsago - TheFly
- 4 days ago - FDA Approves GSK's Hibsago For Chronic Hepatitis B In Adults Without Cirrhosis - Nasdaq
- 4 days ago - GSK (GSK) Gains FDA Approval for Hibsago, Enhancing Dividend Appeal - GuruFocus
- 4 days ago - GSK’s Hibsago approved by FDA for treatment of CHB - TheFly
- 4 days ago - Hibsago (bepirovirsen) Approved in the US for the Treatment of Chronic Hepatitis B (CHB) - Business Wire
- 4 days ago - FDA Approves GSK's Hibsago, Boosting Prospects for Dividend Sustainability (GSK) - GuruFocus